Thus, the emergence of drug-addicted, MEKi-resistant cells, and the opportunity this may afford for intermittent dosing schedules (drug holidays), may be determined by the nature of the amplified driving oncogene (BRAFV600E vs. KRASG13D) further underscoring the difficulties of targeting KRAS mutant tumour cells. The gene discussed is KRAS; the disease is neoplasm.